Author
Listed:
- Andrew J. Gunderson
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Tomoko Yamazaki
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Kayla McCarty
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Nathaniel Fox
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Michaela Phillips
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Alejandro Alice
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Tiffany Blair
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Mark Whiteford
(Earle A. Chiles Research Institute, Providence Cancer Institute
The Oregon Clinic, Colon and Rectal Surgery Division)
- David O’Brien
(Earle A. Chiles Research Institute, Providence Cancer Institute
The Oregon Clinic, Colon and Rectal Surgery Division)
- Rehan Ahmad
(Earle A. Chiles Research Institute, Providence Cancer Institute
The Oregon Clinic, Colon and Rectal Surgery Division)
- Maria X. Kiely
(Earle A. Chiles Research Institute, Providence Cancer Institute
The Oregon Clinic, Colon and Rectal Surgery Division)
- Amanda Hayman
(Earle A. Chiles Research Institute, Providence Cancer Institute
The Oregon Clinic, Colon and Rectal Surgery Division)
- Todd Crocenzi
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Michael J. Gough
(Earle A. Chiles Research Institute, Providence Cancer Institute)
- Marka R. Crittenden
(Earle A. Chiles Research Institute, Providence Cancer Institute
The Oregon Clinic, Radiation Oncology Division)
- Kristina H. Young
(Earle A. Chiles Research Institute, Providence Cancer Institute
The Oregon Clinic, Radiation Oncology Division)
Abstract
Transforming growth factor beta (TGFβ) is a multipotent immunosuppressive cytokine. TGFβ excludes immune cells from tumors, and TGFβ inhibition improves the efficacy of cytotoxic and immune therapies. Using preclinical colorectal cancer models in cell type-conditional TGFβ receptor I (ALK5) knockout mice, we interrogate this mechanism. Tumor growth delay and radiation response are unchanged in animals with Treg or macrophage-specific ALK5 deletion. However, CD8αCre-ALK5flox/flox (ALK5ΔCD8) mice reject tumors in high proportions, dependent on CD8+ T cells. ALK5ΔCD8 mice have more tumor-infiltrating effector CD8+ T cells, with more cytotoxic capacity. ALK5-deficient CD8+ T cells exhibit increased CXCR3 expression and enhanced migration towards CXCL10. TGFβ reduces CXCR3 expression, and increases binding of Smad2 to the CXCR3 promoter. In vivo CXCR3 blockade partially abrogates the survival advantage of an ALK5ΔCD8 host. These data demonstrate a mechanism of TGFβ immunosuppression through inhibition of CXCR3 in CD8+ T cells, thereby limiting their trafficking into tumors.
Suggested Citation
Andrew J. Gunderson & Tomoko Yamazaki & Kayla McCarty & Nathaniel Fox & Michaela Phillips & Alejandro Alice & Tiffany Blair & Mark Whiteford & David O’Brien & Rehan Ahmad & Maria X. Kiely & Amanda Hay, 2020.
"TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking,"
Nature Communications, Nature, vol. 11(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15404-8
DOI: 10.1038/s41467-020-15404-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15404-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.